Immunogenicity of influenza A(H1N1)pdm09 vaccine and the associated factors on lowered immune response in patients with hepatitis C.
BACKGROUND
Patients with underlying disease represent a high-risk group for influenza-associated complications and hospitalization. However, few studies investigated the immunogenicity of influenza vaccine in patients with liver disease.


OBJECTIVE
To examine immunogenicity of influenza A(H1N1)pdm09 vaccine in patients with liver disease and to explore the associated factors on lowered immune response.


METHODS
A single subcutaneous dose of monovalent inactivated unadjuvanted split-virus influenza A(H1N1)pdm09 vaccination was performed in 80 patients with chronic hepatitis C virus infection at Osaka City University Hospital in Japan. To measure the hemagglutination inhibition antibody titer, serum samples were collected before and 3 weeks after vaccination.


RESULTS
No serious adverse events were observed. After vaccination, antibody titers ≥1:40 were observed in 56 patients (71%). The corresponding seroconversion proportion was 72%, and the mean fold rise was 10·3. Immune responses were robust regardless of severity of liver disease or existence of probable cirrhosis. However, patients with older age, lower body mass index, or receiving Stronger Neo-Minophagen C tended to show lower antibody responses to A(H1N1)pdm09 vaccine. In addition, reduced immune responses were observed in patients who had received the 2009/10 seasonal vaccination prior to A(H1N1)pdm09 vaccination.


CONCLUSIONS
Single dose of A(H1N1)pdm09 vaccine achieved a sufficient level of immunity among patients with chronic hepatitis C. Antibody response may be affected by age, body mass index, Stronger Neo-Minophagen C administration, and recent seasonal influenza vaccination.
Department of Public Health, Osaka City University Faculty of Medicine, Osaka, Japan. satop@med.osaka-cu.ac.jp
Satoko
S
Ohfuji
Wakaba
W
Fukushima
Akihiro
A
Tamori
Kazuhiro
K
Maeda
Akiko
A
Maeda
Yoshio
Y
Hirota
D000368:Aged; D000369:Aged, 80 and over; D000914:Antibodies, Viral / Q000276:immunology; D000917:Antibody Formation; D005260:Female; D019698:Hepatitis C, Chronic / Q000150:complications / Q000276:immunology*; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D007251:Influenza, Human / Q000150:complications / Q000276:immunology* / Q000517:prevention & control / Q000821:virology; D007564:Japan; D008297:Male; D008875:Middle Aged; D014611:Vaccination
D000914:Antibodies, Viral; D007252:Influenza Vaccines